No connection

Search Results

ABBV vs EBS

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
EBS
Emergent BioSolutions Inc.
BEARISH
Price
$8.03
Market Cap
$414.7M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
EBS
8.63
Forward P/E
ABBV
15.42
EBS
2.69
P/B Ratio
ABBV
-146.66
EBS
0.8
P/S Ratio
ABBV
6.5
EBS
0.56
EV/EBITDA
ABBV
15.27
EBS
3.8

Profitability

Gross Margin
ABBV
71.46%
EBS
49.44%
Operating Margin
ABBV
35.5%
EBS
-15.2%
Profit Margin
ABBV
4.0%
EBS
7.08%
ROE
ABBV
137.96%
EBS
10.46%
ROA
ABBV
9.59%
EBS
5.33%

Growth

Revenue Growth
ABBV
9.1%
EBS
-23.6%
Earnings Growth
ABBV
-88.7%
EBS
--

Financial Health

Debt/Equity
ABBV
--
EBS
1.12
Current Ratio
ABBV
0.72
EBS
5.01
Quick Ratio
ABBV
0.47
EBS
2.19

Dividends

Dividend Yield
ABBV
3.05%
EBS
--
Payout Ratio
ABBV
490.15%
EBS
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
EBS BEARISH

EBS presents as a classic value trap, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between its Graham Number ($14.48) and Intrinsic Value ($6.51). While the stock appears cheap on a P/E and P/S basis, this is offset by a severe revenue contraction of -23.6% YoY and negative operating margins (-15.20%). The combination of bearish insider sentiment, a 0/100 technical trend, and extreme earnings volatility suggests that the current price is not yet reflecting the full extent of the fundamental decay.

Strengths
Strong short-term liquidity with a Current Ratio of 5.01
Low valuation multiples (P/E 8.63, P/S 0.56)
Healthy Gross Margin of 49.44%
Risks
Significant revenue decline (-23.6% YoY and -24.04% Q/Q)
Negative operating margins indicating an unsustainable core business model
Bearish insider activity with consistent selling and zero buying

Compare Another Pair

ABBV vs EBS: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Emergent BioSolutions Inc. (EBS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile